Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Application
3.3. Market snippet by Route of Administration
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region

4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Comparatively Easier and Less Costly Manufacturing Processes
4.1.1.2. Superior Therapeutic Efficacy and Lower Adverse Effects
4.1.2. Restraints:
4.1.2.1. High Investment Opportunities
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or a Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. Erythropoietin Biobetters*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Insulin Biobetters
7.4. G-CSF Bioreactors
7.5. Monoclonal Antibodies Biobetters
7.6. Anti-Hemophilic Factor
7.7. Other

8. By Application
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
8.1.2. Market Attractiveness Index, By Application Segment
8.2. Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Diabetes
8.4. Renal Disease
8.5. Neurodegenerative Disease
8.6. Genetic Disorders
8.7. Others

9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Subcutaneous
9.4. Inhaled
9.5. Intravenous
9.6. Others

10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacy *
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Pharmacy Stores
10.4. Other

11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of key companies to watch
12.5. List of the company with disruptive technology
12.6. List of start-up companies

13. Company Profiles
13.1. Amgen Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. F. Hoffmann-La Roche AG
13.3. Merck & Co. Inc.
13.4. Sanofi SA
13.5. SERVIER
13.6. Porton Biopharma Limited
13.7. Eli Lily and Company
13.8. Novo Nordisk A/S
13.9. Biogen Inc.
13.10. CSL Behring GmbH(*LIST NOT EXHAUSTIVE)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us